The Efficacy, Mechanism & Safety of Sodium Glucose Co-Transporter-2 Inhibitor & Glucagon-Like Peptide 1 Receptor Agonist Combination Therapy in Kidney Transplant Recipients — StellaPhase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.
Trial locations(1 site)
Canada
Toronto General Hospital, Toronto, Ontario Last updated January 2025